ArriVent BioPharma (AVBP) stock

Cancer medicines , market cap $603M

Medicines for cancer, including lung cancer

Worth $603M

$13.49

-4.73%

As of Tuesday's close · Live for Pro members at the open

Why is AVBP down?

Down 5% on Nov 10.

Its Nov 9 results: net loss widened to $40.3M, from $35M a year before. It fell 5% on Nov 10.

Sources: Price history, Nov 10, 2026; Company release, Nov 9, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time AVBP moves

Free account, no card. An optional alert when AVBP moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →1 more reason why AVBP fell on Nov 10, from its filings, with the other side, the timeline, and its peers, for Pro members.

Quality Score

-7

Poor

In its industry

#253of 281

Biotech

Checks firing

1of 14

Trending down

From 52-week high

-62.3%

under its best in a year

AVBP's Quality Score was unchanged on Tue, Nov 10, at -7.

Follow AVBP's trial news. Pro members can get an alert when ArriVent BioPharma files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AVBP files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2027“milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027.”Trial data · SEC filing · Oct 26

Key facts on AVBP

Key facts on AVBP
Holding it back	Moves 12.4% a day with no profit behind it
Latest filing	8-K, Nov 9 Reported its quarterly results and reported a change of officers or directors

1 more reason behind AVBP's -7, free with an account →3 more reasons behind AVBP's -7, for Pro members.

AVBP in the news

ReportLast night: a loss of $0.81 a share. Past reports ›

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

AVBP catalysts

Coming up

After its last 4 reports it closed -4.2% on average, higher 0 of 4 times.

3 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for AVBP, and how long its cash lasts

Next step the company has named

2027“milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027.”Trial data · SEC filing · Oct 26

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing Uncommon MutationsPhase 3 · Recruiting · 480 people · main data estimated Feb 2029 · NCT07185997

4 more trials, 34 filings, for Pro members.

Cash runway

The company says its cash lasts into 2028 (8-K, Aug 12).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 3, 2025)
At-the-market share sales program (424B5, filed May 11, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Zhengbin Yao buys or sells

For Pro members: every trade, and Zhengbin Yao’s 2 filings and quotes.

Get an alert when AVBP files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How AVBP ranks in Biotech

AVBP is #253 of 281 by Quality Score.

How AVBP ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	AURAAura Biosciences		Open for its score
	AUTLAutolus Therapeutics		Open for its score
	AVIRAtea Pharmaceuticals		Open for its score
	AVLNAvalyn Pharma		Open for its score
253	AVBPArriVent BioPharma	1/14	-7

When does AVBP report earnings, and what happens after?

Expected to report Mon Mar 8, after the close (in 118 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What AVBP reported on Nov 9, 2026

The quarter

A loss of $0.81 a share, from $0.83.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

AVBP's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value: $603M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on AVBP: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.2%-4.6%-4.7%

May 11Aug 12Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026After close	After close	+0.6%	-4.7%	not yet
Aug 12, 2026After close	After close	-2.3%	-4.6%	-4.6%
May 11, 2026After close	After close	-2.2%	-0.2%	-6.8%

AVBP closed higher after 0 of its last 4 reports.

All 4 reports, and AVBP's Quality Score going into each

AVBP has 1 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on AVBP, and all 14 on every stock.Get in free →

AVBP RSI today: 35.4, below its 50-day and 200-day averages

Not scored

RSI 35.4, MACD above signal, below both averages. Not scored.13 readings

The deep dive on AVBP

What it does and how it makes money2 findingsFor Pro members2 findings on what AVBP does and how it makes money, for Pro members
Where it stands2 findings2 offerings of shares or notes since Jul 2025, $298M in all.SEC filing · May 11, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades AVBP, for Pro members

5 more findings on AVBP, each with its source, for Pro members.

AVBP share count over time

Shares: 18.2% more than a year ago (to Sep 30).

Shares of AVBP outstanding, as filed
Shares outstanding	As of
51.7M	Nov 5, 2026
49.3M	Aug 10, 2026
46.6M	May 8, 2026
44.2M	Mar 4, 2026

Offerings, shelves, and splits of AVBP, from its filings
From its filings	Filed
Set up an at-the-market program for up to $250M of shares, about 41% of its market value	May 11, 2026
Raised $48.4M in a sale of shares, about 8% of its market value	Jul 2, 2025
Registered shares for a later sale (S-3ASR)	Feb 3, 2025
Raised $175M in a sale of shares, about 29% of its market value	Jan 26, 2024

AVBP's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Robin LaChapelleChief Operating Officer · no trades on file

See insider trades by person

Which ETFs hold AVBP?

In ETFs: AVBP is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About ArriVent BioPharma

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

77 employeesNewtown Square, PAarrivent.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on AVBP and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn AVBP's score around: 8 things
10 more filings explained, a plain line each
4 more things pulling AVBP's score down

See AVBP's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: AVBP's Quality Score is -7 (Poor), #253 of 281 in Biotech.

What does AVBP's Quality Score say?

AVBP scores -7 today, which Breakaway calls Poor. It is #253 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 5% on Nov 10. Shares: 18.2% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is AVBP's Quality Score?

AVBP scores -7 today, which Breakaway calls Poor (below zero). That is #253 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AVBP's -7.

When does AVBP report earnings?

Expected to report Mon Mar 8, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. AVBP closed higher after 0 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.